1083181-43-4 Usage
General Description
6-Bromo-1-Methyl-1H-benzo[d][1,2,3]triazole is a chemical compound with the molecular formula C8H6BrN3. It is a heterocyclic organic compound and a derivative of benzotriazole, which is commonly used as a corrosion inhibitor in various industrial applications. 6-BroMo-1-Methyl-1H-benzo[d][1,2,3]triazole is also utilized as an intermediate in the synthesis of pharmaceuticals and agricultural chemicals. Additionally, it has shown potential as a building block for the development of new materials and bioactive molecules. Its chemical structure and properties make it a versatile and valuable compound for a wide range of manufacturing and research purposes.
Check Digit Verification of cas no
The CAS Registry Mumber 1083181-43-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,3,1,8 and 1 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1083181-43:
(9*1)+(8*0)+(7*8)+(6*3)+(5*1)+(4*8)+(3*1)+(2*4)+(1*3)=134
134 % 10 = 4
So 1083181-43-4 is a valid CAS Registry Number.
InChI:InChI=1/C7H6BrN3/c1-11-7-4-5(8)2-3-6(7)9-10-11/h2-4H,1H3
1083181-43-4Relevant articles and documents
COMPOUNDS AND THEIR METHODS OF USE
-
, (2021/11/20)
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.
BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS
-
, (2011/02/24)
The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.
